Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
AssigneeGenentech, Inc.
InventorsBrian C. Cunningham, Henry Lowman, James A. Wells
Life of this patent
Estimating the term…
Abstract
Human growth hormone variants are disclosed wherein the lysine at position 41 and/or the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone, has been replaced with another amino acid. Also claimed are combination variants that have a higher binding affinity to the growth hormone receptor than wild-type human growth hormone.
Claims4
A human growth hormone variant having at least one amino acid substitution selected from the group consisting of the lysine at position 41 and the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone.
A human growth hormone variant having at least two amino acid residues replaced with different amino acid residues, wherein the variant has a set of amino acid substitutions selected from the group consisting of F54P,E56D, I58T,R64K;
- F54P,E56W,I58T,R64K;
- and F54P,R64K, numbered from the mature N-terminus of 191-amino acid human growth hormone.
A composition comprising a human growth hormone variant having at least one amino acid substitution selected from the group consisting of the lysine at position 41 and the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.